Go Pro
Mayank Mamtani

Mayank Mamtani Analyst Performance

Senior Managing Director & Group Head of Healthcare at B. Riley Financial

Mayank Mamtani is a stock analyst at B. Riley Financial in the healthcare sector, covering 41 publicly traded companies. Over the past year, Mayank Mamtani has issued 41 stock ratings, including strong buy, buy, and hold recommendations. While full access to Mayank Mamtani's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Mayank Mamtani's coverage history, rating activity, and performance tendencies - helping individual investors make more informed trading decisions.

Analyst Rankings, Coverage, and Performance Statistics

Average Return
00.00% 12-Month ROI
Success Rate
00.00% Profitable Ratings
Total Ratings
150 Last 7 Years
Buy Recommendations
95.14% 137 Buy Ratings
Companies Covered
41 Unique Companies

Ratings Distribution

RatingPercentageCount
Strong Buy3.5%5 ratings
Buy91.7%132 ratings
Hold4.9%7 ratings
Sell0.0%0 ratings

Out of 144 total stock ratings issued by Mayank Mamtani at B. Riley Financial, the majority (91.7%) have been Buy recommendations, followed by 4.9% Hold and 3.5% Strong Buy.

Exchange Coverage

ExchangePercentageCount
NASDAQ
87.8% of companies on NASDAQ
36 companies
NYSE
4.9% of companies on NYSE
2 companies
OTCMKTS
4.9% of companies on OTCMKTS
2 companies
NYSEAMERICAN
2.4% of companies on NYSEAMERICAN
1 company

Mayank Mamtani, an analyst at B. Riley Financial, currently covers 41 companies listed on NASDAQ, NYSE, OTCMKTS and NYSEAMERICAN, with the majority traded on NASDAQ.

Coverage Focus

Sector IconSectorPercentage
Healthcare
41 companies
100.0%

Mayank Mamtani of B. Riley Financial specializes in stock coverage within the Healthcare sector.

Coverage Industries

IndustryPercentage
BIOTECHNOLOGY
28 companies
68.3%
PHARMACEUTICALS
13 companies
31.7%

Mayank Mamtani's Ratings History at B. Riley Financial

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription
12-Month ROIUpgrade to All Access to use the All ROI Filter
CompanyReport DateActionReport Date Price12-Month
Price Target
Rating12-Month
Price & ROI
Details
Denali Therapeutics Inc. stock logo
DNLI
Denali Therapeutics
8/25/2026Boost Price Target$24.96$35.00Buy
4D Molecular Therapeutics, Inc. stock logo
FDMT
4D Molecular Therapeutics
8/17/2026Reiterated Rating$14.34Buy
MacroGenics, Inc. stock logo
MGNX
MacroGenics
8/17/2026Boost Price Target$4.13$11.00Buy
Journey Medical Corporation stock logo
DERM
Journey Medical
8/13/2026Reiterated Rating$6.43$15.00Buy
Unicycive Therapeutics, Inc. stock logo
UNCY
Unicycive Therapeutics
8/12/2026Reiterated Rating$5.38$20.00Buy
Zymeworks Inc. stock logo
ZYME
Zymeworks
8/10/2026Reiterated Rating$24.10$44.00Buy
4D Molecular Therapeutics, Inc. stock logo
FDMT
4D Molecular Therapeutics
7/31/2026Initiated Coverage$10.07$37.00Buy
Agenus Inc. stock logo
AGEN
Agenus
7/30/2026Reiterated Rating$6.84$14.00Buy
Trevi Therapeutics, Inc. stock logo
TRVI
Trevi Therapeutics
7/20/2026Boost Price Target$19.01$31.00Buy
Veradermics, Incorporated stock logo
MANE
Veradermics
7/15/2026Initiated Coverage$109.85$170.00Buy
Unicycive Therapeutics, Inc. stock logo
UNCY
Unicycive Therapeutics
6/30/2026Reiterated Rating$4.14$22.00Buy
Ascentage Pharma Group International - Unsponsored ADR stock logo
AAPG
Ascentage Pharma Group International
6/10/2026Initiated Coverage$17.07$45.00Buy
Elicio Therapeutics, Inc. stock logo
ELTX
Elicio Therapeutics
6/10/2026Initiated Coverage$14.20$27.00Buy
MacroGenics, Inc. stock logo
MGNX
MacroGenics
4/10/2026Upgrade$3.44$9.00Buy
Theravance Biopharma, Inc. stock logo
TBPH
Theravance Biopharma
4/7/2026Boost Price Target$16.42$17.00Neutral
Harrow, Inc. stock logo
HROW
Harrow
4/7/2026Reiterated Rating$34.91$65.00Buy
Lineage Cell Therapeutics, Inc. stock logo
LCTX
Lineage Cell Therapeutics
3/25/2026Boost Price Target$1.60$4.00Buy
Climb Bio, Inc. stock logo
CLYM
Climb Bio
3/24/2026Initiated Coverage$6.54$26.00Buy
Climb Bio, Inc. stock logo
CLYM
Climb Bio
3/23/2026Upgrade$6.98Strong-Buy
Arcturus Therapeutics Holdings Inc. stock logo
ARCT
Arcturus Therapeutics
3/18/2026Initiated Coverage$6.39$22.00Buy
Arcturus Therapeutics Holdings Inc. stock logo
ARCT
Arcturus Therapeutics
3/17/2026Upgrade$6.72Strong-Buy
Theravance Biopharma, Inc. stock logo
TBPH
Theravance Biopharma
3/4/2026Reiterated Rating$13.96$14.00Neutral
Nektar Therapeutics stock logo
NKTR
Nektar Therapeutics
2/23/2026Reiterated Rating$71.87$150.00Buy
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
1/21/2026Boost Price Target$63.78$108.00Buy
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
12/11/2025Boost Price Target$552.47$670.00Buy
Opus Genetics, Inc. stock logo
IRD
Opus Genetics
12/10/2025Initiated Coverage$2.39$9.00Buy
Centessa Pharmaceuticals PLC Sponsored ADR stock logo
CNTA
Centessa Pharmaceuticals
12/1/2025Boost Price Target$29.11$42.00Buy
Zymeworks Inc. stock logo
ZYME
Zymeworks
11/21/2025Reiterated Rating$23.82$40.00Buy
Nuvation Bio Inc. stock logo
NUVB
Nuvation Bio
11/19/2025Initiated Coverage$4.80$12.00Buy
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
11/10/2025Reiterated Rating$61.01$90.00Buy
Novavax, Inc. stock logo
NVAX
Novavax
11/10/2025Reiterated Rating$7.23$16.00Buy
TG Therapeutics, Inc. stock logo
TGTX
TG Therapeutics
11/4/2025Upgrade$33.81Strong-Buy
Zymeworks Inc. stock logo
ZYME
Zymeworks
10/10/2025Initiated Coverage$16.92$30.00Buy
Harrow, Inc. stock logo
HROW
Harrow
10/1/2025Reiterated Rating$48.18$74.00Buy
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
9/29/2025Boost Price Target$439.05$560.00Buy
Nektar Therapeutics stock logo
NKTR
Nektar Therapeutics
9/23/2025Boost Price Target$58.63$105.00Buy
Harrow, Inc. stock logo
HROW
Harrow
9/23/2025Boost Price Target$48.61$70.00Buy
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
9/22/2025Boost Price Target$49.04$80.00Buy
TG Therapeutics, Inc. stock logo
TGTX
TG Therapeutics
9/17/2025Boost Price Target$32.51$55.00Buy
Theravance Biopharma, Inc. stock logo
TBPH
Theravance Biopharma
9/12/2025Initiated Coverage$13.70$28.00Buy
The cat is out the bag (Ad)

Almost 80,000 tech jobs vanished in the first three months of 2026. Meta cut 14,000 roles, Microsoft offered separation packages to 8,500 workers, and Oracle is reportedly eliminating up to 30,000 positions. Goldman Sachs estimates 12,400 Americans are being financially displaced every single day. Analyst Porter Stansberry says the real driver runs deeper than AI - and two Nobel Prize winners have issued the same warning. He calls it the Final Displacement, and he's releasing a full investigation with specific companies to buy and sell before the next wave hits.tc pixel

Watch Porter Stansberry's full investigation into the Final Displacement now
Theravance Biopharma, Inc. stock logo
TBPH
Theravance Biopharma
9/11/2025Upgrade$14.30Strong-Buy
Actuate Therapeutics, Inc. stock logo
ACTU
Actuate Therapeutics
8/26/2025Initiated Coverage$7.98$20.00Buy
Altimmune, Inc. stock logo
ALT
Altimmune
8/13/2025Lower Price Target$3.62$18.00Buy
MediciNova, Inc. stock logo
MNOV
MediciNova
6/16/2025Upgrade$1.31$5.00Strong-Buy
MacroGenics, Inc. stock logo
MGNX
MacroGenics
5/20/2025Lower Price Target$1.57$3.00Neutral
Harrow, Inc. stock logo
HROW
Harrow
4/1/2025Lower Price Target$25.23$65.00Buy
Vaxart, Inc. stock logo
VXRT
Vaxart
3/27/2025Lower Price Target$0.45$2.00Buy
Trevi Therapeutics, Inc. stock logo
TRVI
Trevi Therapeutics
3/19/2025Reiterated Rating$6.69$20.00Buy
Lineage Cell Therapeutics, Inc. stock logo
LCTX
Lineage Cell Therapeutics
3/14/2025Lower Price Target$0.52$3.00Buy
Denali Therapeutics Inc. stock logo
DNLI
Denali Therapeutics
3/5/2025Reiterated Rating$16.06$35.00Buy
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
2/14/2025Reiterated Rating$19.75$38.00Buy